Cited by 7,810Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Open access

Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Bouché, Olivier, Guimbaud, Rosine, Bécouarn, Yves, Adenis, Antoine, Raoul, Jean-Luc, Gourgou-Bourgade, Sophie, de la Fouchardière, Christelle, Bennouna, Jaafar, Bachet, Jean-Baptiste, Khemissa-Akouz, Faiza, Péré-Vergé, Denis, Delbaldo, Catherine, Assenat, Eric, Chauffert, Bruno, Michel, Pierre, Montoto-Grillot, Christine, Ducreux, Michel·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1011923

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS: The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS: As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011923

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

Zeghari-Squalli N, 1999, Clin Cancer Res, 5, 1189
10.2307/2281868 · DOI · Paper page
Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.

Sorted by citations

Items 601–700 of 1,032

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
Luheshi, N., Ulrichsen, J. C., Harper, J. A., Mullins, S., Sulikowski, M., Martin, P., Brown, L., Lewis, A. R., Davies, G. C., Morrow, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7610 · Cited by 100
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Muranaka, T., Kuwatani, M., Komatsu, Y., Sawada, K., Nakatsumi, H., Kawamoto, Y., Yuki, S., Kubota, Y., Kubo, K., Kawahata, S., et al. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.02.02 · Cited by 98
Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy
van Veldhuisen, E., Vogel, J. A., Klompmaker, S., Busch, O. R., van Laarhoven, H. W. M., van Lienden, K. P., Wilmink, J. W., Marsman, H. A., & Besselink, M. G. (2018) · HPB · doi:10.1016/j.hpb.2018.01.001 · Cited by 97
EMT and Stemness—Key Players in Pancreatic Cancer Stem Cells
Rodríguez-Aznar, E., Wiesmüller, L., Sáinz, B., & Hermann, P. C. (2019) · Cancers · doi:10.3390/cancers11081136 · Cited by 99
Understanding resistance to combination chemotherapy
Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.003 · Cited by 100
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Re, M. D., Vivaldi, C., Rofi, E., Vasile, E., Miccoli, M., Caparello, C., d’Arienzo, P. D., Fornaro, L., Falcone, A., & Danesi, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-08297-z · Cited by 96
The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer
Brunetto, E., Monte, L. B. D., Balzano, G., Camisa, B., Laino, V., Riba, M., Heltai, S., Bianchi, M. E., Bordignon, C., Falconi, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0521-4 · Cited by 97
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Overman, M. J., Javle, M. M., Davis, R. E., Vats, P., Kumar‐Sinha, C., Xiao, L., Mettu, N. B., Parra, E. R., Benson, A. B., Lopez, C. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000587 · Cited by 97
Prognostic and predictive factors in pancreatic cancer
Dell’Aquila, E., Fulgenzi, C. A. M., Minelli, A., Citarella, F., Stellato, M., Pantano, F., Russano, M., Cursano, M. C., Napolitano, A., Zeppola, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27518 · Cited by 101
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
Ozaka, M., Nakachi, K., Kobayashi, S., Ohba, A., Imaoka, H., Terashima, T., Ishii, H., Mizusawa, J., Katayama, H. G., Kataoka, T., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.014 · Cited by 99
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Neuzillet, C., Hammel, P. R., Tijeras‐Raballand, A., Couvelard, A., & Raymond, É. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9396-2 · Cited by 97
Recent studies of 5-fluorouracil resistance in pancreatic cancer
Wang, W. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15682 · Cited by 95
Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205
Chaudhary, A., Mondal, G., Kumar, V., Kattel, K., & Mahato, R. I. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.007 · Cited by 95
Pancreatic cancer microenvironment: a current dilemma
Uzunparmak, B., & Şahin, İ. H. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0221-1 · Cited by 95
Medical treatment for cholangiocarcinoma
Adeva, J., Sangro, B., Salati, M., Edeline, J., Casta, A. L., Bittoni, A., Berardi, R., Bruix, J., & Valle, J. W. (2019) · Liver International · doi:10.1111/liv.14100 · Cited by 97
Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia?
Obaid, G., Bano, S., Mallidi, S., Broekgaarden, M., Kuriakose, J., Silber, Z., Bulin, A., Wang, Y.-C., Mai, Z., Jin, W., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b00859 · Cited by 96
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice
Peran, I., Dakshanamurthy, S., McCoy, M., Mavropoulos, A., Allo, B. A., Sebastian, A., Hum, N. R., Sprague, S. C., Martin, K. A., Pishvaian, M. J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.11.044 · Cited by 96
Neoadjuvant therapy for pancreatic cancer
Gugenheim, J., Crovetto, A., & Petrucciani, N. (2021) · Updates in Surgery · doi:10.1007/s13304-021-01186-1 · Cited by 95
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Klein-Brill, A., Amar-Farkash, S., Lawrence, G. M., Collisson, E. A., & Aran, D. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.16199 · Cited by 98
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Wang‐Gillam, A., Plambeck-Suess, S. M., Goedegebuure, P. S., Simon, P. O., Mitchem, J. B., Hornick, J. R., Sorscher, S. M., Picus, J., Suresh, R., Lockhart, A. C., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9866-y · Cited by 97
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00124 · Cited by 94
Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
Nishida, S., Koido, S., Takeda, Y., Homma, S., Komita, H., Takahara, A., Morita, S., Ito, T., Morimoto, S., Hara, K., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000020 · Cited by 94
Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer
Tam, V. C., Ko, Y. J., Mittmann, N., Cheung, M. C., Kumar, K., Hassan, S., & Chan, K. (2013) · Current Oncology · doi:10.3747/co.20.1223 · Cited by 94
Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
Kulemann, B., Rösch, S., Seifert, S., Timme, S., Bronsert, P., Seifert, G. J., Martini, V., Kuvendjiska, J., Glatz, T., Hussung, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04601-z · Cited by 96
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
Macarulla, T. M., Pazo-Cid, R., Guillén‐Ponce, C., López‐López, R., Vera, R., Reboredo, M., Martín, A. J. M., Rivera, F., Beveridge, R. D., Casta, A. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00089 · Cited by 94
Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes
Frère, C., Bournet, B., Gourgou, S., Fraisse, J., Canivet, C., Connors, J. M., Buscail, L., Farge, D., Bournet, B., Canivet, C., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.12.009 · Cited by 95
Self-citation
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
Suzuki, S., Okada, M., Shibuya, K., Seino, M., Satō, A., Takeda, H., Seino, S., Yoshioka, T., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2693 · Cited by 94
Randomized phase II / III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐ PC Study
Yamaue, H., Tsunoda, T., Tani, M., Miyazawa, M., Yamao, K., Mizuno, N., Okusaka, T., Ueno, H., Boku, N., Fukutomi, A., et al. (2015) · Cancer Science · doi:10.1111/cas.12674 · Cited by 94
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
Tong, H., Fan, Z., Liu, B., & Lu, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-26811-9 · Cited by 96
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B. G., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00505-0 · Cited by 93
Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside
Oettle, H. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.003 · Cited by 98
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 97
TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer
Grimmig, T., Matthes, N., Hoeland, K. M., Tripathi, S., Chandraker, A. K., Grimm, M. R., Moench, R., Moll, E.-M., Friess, H., Tsaur, I., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3069 · Cited by 93
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Riva, F., Dronov, O. I., Khomenko, D. I., Huguet, F., Louvet, C., Mariani, P., Stern, M., Lantz, O. J., Proudhon, C., Pierga, J., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.006 · Cited by 97
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial
Bockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., Rasco, D. W., Jones, S. F., Smith, L. S., Cox, D. S., Durante, M., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.020 · Cited by 93
Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro
Johnson, J. L., & de Mejı́a, E. G. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.036 · Cited by 92
Systemic Therapy for Metastatic Pancreatic Cancer
Ettrich, T. J., & Seufferlein, T. T. W. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00895-4 · Cited by 94
IP-10/CXCL10 attracts regulatory T cells: Implication for pancreatic cancer
Lunardi, S., Lim, S. Y., Muschel, R. J., & Brunner, T. B. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027473 · Cited by 96
Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
Tzeng, C.-W. D., Fleming, J. B., Lee, J. E., Wang, X., Pisters, P. W. T., Vauthey, J., Varadhachary, G., Wolff, R. A., & Katz, M. H. G. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00445.x · Cited by 92
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial
Reni, M., Cereda, S., Milella, M., Novarino, A., Passardi, A., Mambrini, A., Lucca, G. D., Aprile, G., Belli, C., Danova, M., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.041 · Cited by 92
Hippo pathway mediates resistance to cytotoxic drugs
Gujral, T. S., & Kirschner, M. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703096114 · Cited by 91
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience
Nitsche, U., Wenzel, P., Siveke, J. T., Braren, R., Holzapfel, K., Schlitter, A. M., Stöß, C., Kong, B., Esposito, I., Erkan, M., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4851-2 · Cited by 91
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Muckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 95
Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety
Inoue, Y., Saiura, A., Oba, A., Kawakatsu, S., Ono, Y., Sato, T., Mise, Y., Ishizawa, T., Takahashi, Y., & Ito, H. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3995-3 · Cited by 92
The Role of Exosomes in Pancreatic Cancer
Lan, B., Zeng, S., Grützmann, R., & Pilarsky, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184332 · Cited by 94
New therapeutic targets in pancreatic cancer
Lai, E., Puzzoni, M., Ziranu, P., Pretta, A., Impera, V., Mariani, S., Liscia, N., Soro, P., Musio, F., Persano, M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101926 · Cited by 94
Pancreatoduodenectomy at the Verona Pancreas Institute: the Evolution of Indications, Surgical Techniques, and Outcomes
Bassi, C., Marchegiani, G., Giuliani, T., Gioia, A. D., Andrianello, S., Zingaretti, C. C., Brentegani, G., Pastena, M. D., Fontana, M., Pea, A., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004753 · Cited by 91
Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label therapy
Hirt, C., Booij, T. H., Grob, L., Simmler, P., Toussaint, N. C., Keller, D., Taube, D., Ludwig, V., Goryachkin, A., Pauli, C., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100095 · Cited by 92
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Robatel, S., & Schenk, M. (2022) · Cancers · doi:10.3390/cancers14040985 · Cited by 94
High intensity focused ultrasound: A noninvasive therapy for locally advanced pancreatic cancer
Wu, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16480 · Cited by 91
Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome
Mohammad, G. H., Damink, S. W. M. O., Malagó, M., Dhar, D. K., & Pereira, S. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151635 · Cited by 93
Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians
Spadi, R. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.27 · Cited by 90
Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF 1‐dependent pathway
Chen, K., Qian, W., Li, J., Jiang, Z., Cheng, L., Yan, B., Cao, J., Sun, L., Zhou, C., Lei, M., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12116 · Cited by 92
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Giordano, G., Pancione, M., Olivieri, N., Parcesepe, P., Velocci, M., Raimo, T. D., Coppola, L., Toffoli, G., & D'Andrea, M. R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i32.5875 · Cited by 93
Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study
Rivera, F., Benavides, M., Gallego-Plazas, J., Guillén‐Ponce, C., Lopez-Martin, J. A., & Küng, M. (2018) · Pancreatology · doi:10.1016/j.pan.2018.10.004 · Cited by 90
The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 91
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
Porcelli, L., Iacobazzi, R. M., Fonte, R., Serratì, S., Intini, A., Solimando, A. G., Brunetti, O., Calabrese, A., Leonetti, F., Azzariti, A., et al. (2019) · Cancers · doi:10.3390/cancers11030330 · Cited by 90
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer
Forero, A., Infante, J. R., Waterhouse, D. M., Wong, L., Vickers, S. M., Arrowsmith, E. R., He, A. R., Hart, L. L., Trent, D. F., Wade, J. L., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.137 · Cited by 90
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
Zaniboni, A., Aitini, E., Barni, S., Ferrari, D., Cascinu, S., Catalano, V., Valmadre, G., Ferrara, D., Veltri, E. M., Codignola, C., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1875-1 · Cited by 90
Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer
Riihimäki, M., Thomsen, H., Hemminki, A., Sundquist, K., & Hemminki, K. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-36 · Cited by 90
The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer
Gobbi, P. G., Bergonzi, M., Comelli, M., Villano, L., Pozzoli, D., Vanoli, A., & Dionigi, P. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.002 · Cited by 90
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Venkatesha, V. A., Parsels, L. A., Parsels, J. D., Zhao, L., Zabludoff, S., Simeone, D. M., Maybaum, J., Lawrence, T. S., & Morgan, M. A. (2012) · Neoplasia · doi:10.1593/neo.12538 · Cited by 91
Fractionated radioimmunotherapy with 90 Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer
Ocean, A. J., Pennington, K. L., Guarino, M. J., Sheikh, A., Bekaii‐Saab, T., Serafini, A. N., Lee, D. C., Sung, M. W., Güleç, S., Goldsmith, S. J., et al. (2012) · Cancer · doi:10.1002/cncr.27592 · Cited by 89
Combinational therapy: New hope for pancreatic cancer?
Shi, S., Yao, W., Xu, J., Long, J., Liu, C., & Yu, X. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.029 · Cited by 89
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
Chiorean, E. G., Hoff, D. D. V., Tabernero, J. M., El-Maraghi, R. H., Ma, W. W., Reni, M., Harris, M., Whorf, R. C., Liu, H. W., Li, J. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.185 · Cited by 90
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis
Wright, G. P., Poruk, K. E., Zenati, M. S., Steve, J., Bahary, N., Hogg, M. E., Zuriekat, A., Wolfgang, C. L., Zeh, H. J., & Weiss, M. J. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-016-3256-2 · Cited by 90
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
Glassman, D. C., Palmaira, R. L. D., Covington, C. M., Desai, A. M., Ku, G. Y., Li, J., Harding, J. J., Varghese, A. M., O'Reilly, E. M., & Yu, K. H. (2018) · BMC Cancer · doi:10.1186/s12885-018-4605-1 · Cited by 89
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort
Pietrasz, D., Turrini, O., Vendrely, V., Simon, J.-M., Hentic, O., Coriat, R., Portales, F., Roy, B. L., Taı̈eb, J., Régenet, N., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6931-6 · Cited by 89
Self-citation
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
Chan, K., Guo, H., Cheng, S., Beca, J. M., Redmond‐Misner, R., Isaranuwatchai, W., Qiao, L., Earle, C. C., Berry, S. R., Biagi, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2705 · Cited by 91
Safety Considerations of Cancer Nanomedicine—A Key Step toward Translation
Liu, X., Tang, I., Wainberg, Z. A., & Meng, H. (2020) · Small · doi:10.1002/smll.202000673 · Cited by 90
Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: Roles in cancer progression and therapeutic response
Ashrafizadeh, M., Mohan, C. D., Rangappa, S., Zarrabi, A., Hushmandi, K., Kumar, A. P., Sethi, G., & Rangappa, K. S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21950 · Cited by 89
Pancreatic Neoplasm in 2011: An Update
Saif, M. W. (2015) · PubMed · doi:10.6092/1590-8577/3071 · Cited by 89
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
Catanese, S., Pentheroudakis, G. E., Douillard, J.-Y., & Lordick, F. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000804 · Cited by 89
Inhibiting autophagy to prevent drug resistance and improve anti-tumor therapy
Ramirez, J. A. Z., Romagnoli, G. G., & Kaneno, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118745 · Cited by 91
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?
Marech, I., Patruno, R., Zizzo, N., Gadaleta, C., Introna, M., Zito, A. F., Gadaleta, C. D., & Ranieri, G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.011 · Cited by 90
Perioperative and Long-Term Outcome after Standard Pancreaticoduodenectomy, Additional Portal Vein and Multivisceral Resection for Pancreatic Head Cancer
Kulemann, B., Hoeppner, J., Wittel, U. A., Glatz, T., Keck, T., Wellner, U. F., Bronsert, P., Sick, O., Hopt, U. T., Makowiec, F., et al. (2015) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-014-2725-8 · Cited by 88
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
Kausar, T., Schreiber, J. S., Karnak, D. M., Parsels, L. A., Parsels, J. D., Davis, M. A., Zhao, L., Maybaum, J., Lawrence, T. S., & Morgan, M. A. (2015) · Neoplasia · doi:10.1016/j.neo.2015.09.006 · Cited by 88
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
Duong, H., Hwang, J. S., Kim, H. J., Kang, H. J., Seong, Y., & Bae, I. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1516 · Cited by 91
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Caparello, C., Meijer, L. L., Garajová, I., Falcone, A., Large, T. Y. S. L., Funel, N., Geert Kazemier, M., Peters, G. J., Vasile, E., & Giovannetti, E. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.6987 · Cited by 90
Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy
Mellon, E. A., Jin, W. H., Frakes, J. M., Centeno, B. A., Strom, T. J. C., Springett, G. M., Malafa, M. P., Shridhar, R., Hodul, P. J., & Hoffe, S. E. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1256497 · Cited by 87
Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies
Ruarus, A. H., Vroomen, L. G. P. H., Puijk, R. S., Scheffer, H. J., & Meijerink, M. R. (2018) · Cancers · doi:10.3390/cancers10010016 · Cited by 87
The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer – A systematic review
Hakeem, A. R., Papoulas, M., & Menon, K. V. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.08.020 · Cited by 87
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 97
Self-citation
Single Extracellular VEsicle Nanoscopy
Saftics, A., Abuelreich, S., Romano, E., Ghaeli, I., Jiang, N., Spanos, M., Lennon, K. M., Singh, G. P., Das, S., Keuren‐Jensen, K. R. V., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12346 · Cited by 89
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer
Togashi, Y., Kogita, A., Sakamoto, H., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., Tomida, S., Kitano, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.037 · Cited by 89
Survival Among Patients With Pancreatic Cancer and Long-Standing or Recent-Onset Diabetes Mellitus
Yuan, C., Rubinson, D. A., Qian, Z. R., Wu, C. H., Kraft, P. L., Bao, Y., Ogino, S., Ng, K., Clancy, T. E., Swanson, R. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5688 · Cited by 87
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells
Chien, W., Ding, L., Sun, Q., Fernández, L. T., Tan, S. Z., Xiao, J.-F., Lim, S. L., Garg, M., Lee, K. L., Kitajima, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2051 · Cited by 89
Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
Lim, K., Chung, E., Khan, A. S., Cao, D., Linehan, D. C., Ben‐Josef, E., & Wang‐Gillam, A. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0268 · Cited by 87
Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer
Polvani, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2441 · Cited by 89
Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells
Trabulo, S. M. D., Aires, A., Aicher, A., Heeschen, C., & Cortajarena, A. L. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.01.035 · Cited by 87
miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies
Chitkara, D., Mittal, A., & Mahato, R. I. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.006 · Cited by 86
The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models
Mizuma, M., Rasheed, Z. A., Yabuuchi, S., Omura, N., Campbell, N. R., de Wilde, R. F., Oliveira, E. D., Zhang, Q., Puig, Ó., Matsui, W. H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0017 · Cited by 86
Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
Okusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 88
Dithiocarbazate-Copper Complexes for Bioimaging and Treatment of Pancreatic Cancer
Gou, Y., Chen, M., Li, S., Deng, J., Li, J., Fang, G., Yang, F., & Huang, G. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01936 · Cited by 86
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 87
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
Eshmuminov, D., Aminjonov, B., Palm, R. F., Malleo, G., Schmocker, R. K., Abdallah, R., Yoo, C., Shaib, W. L., Schneider, M. A., Rangelova, E. B., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13353-2 · Cited by 87

Authors: Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.-B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M.
Affiliations: Centre Léon Bérard (FR)
Centre Hospitalier Universitaire de Reims (FR)
Institut Claudius Regaud (FR)
Institut Bergonié (FR)
Centre Oscar Lambret (FR)
Centre Eugène Marquis (FR)
Hôpital Ambroise-Paré (FR)
Centre Hospitalier de Perpignan (FR)
Hôpital de la Croix-Rousse (FR)
Centre Hospitalier Universitaire Henri-Mondor (FR)
Centre Georges François Leclerc (FR)
Université de Rouen Normandie (FR)
UniCancer Group (FR)
Institut Gustave Roussy (FR)
ORCID: Conroy, Thierry
Ychou, Marc
Bouché, Olivier
Guimbaud, Rosine
Adenis, Antoine
Raoul, Jean-Luc
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-05-12
Volume: 364
Issue: 19
Pages: 1817-1825
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1011923
OpenAlex: W2151253787
Cited by: 7,810
References: 37
Citations by year: 2026: 425 · 2025: 521 · 2024: 560 · 2023: 604 · 2022: 622 · 2021: 785 · 2020: 692 · 2019: 563 · 2018: 577 · 2017: 558 · 2016: 454 · 2015: 473 · 2014: 388 · 2013: 282 · 2012: 222
FWCI: 150.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: FOLFIRINOX, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, overall survival, progression-free survival, objective response rate, febrile neutropenia, quality of life, adverse events, combination chemotherapy, randomized trial comparison
MeSH terms: Irinotecan, Oxaliplatin, Gemcitabine, Adenocarcinoma, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Pancreatic Neoplasms, Quality of Life, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks